METHOD AND MEANS OF ANXIETY-DEPRESSION DISORDERS CORRECTION IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH 2ND TYPE DIABETES

Abstract

Aim. To elaborate the method and means for correction of anxiety-depression disorders in patients with arterial hypertension (AH) associated with 2nd type diabetes mellitus. Material and methods. Totally 120 patients included with essential arterial hypertension (AH), associated with 2nd type DM, non-sufficient control of В P. Patients with AH had the second grade of BP increase at the background of 2nd type DM of mild or moderate severity compensated according to the levels of glycosilated hemoglobin 6,25%. Patients had quite high amount of comorbidities and risk factors complicating AH. All patients were taking basic ant hypertension therapy, mostly a variety of combinations of drugs (beta-blockers, ACE inhibitors, calcium antagonists,angiotensine receptor blockers II). Also the patients took the drugs for comorbidities treatment (hypolipidemic drugs, nitrates, glucose lowering drugs). The necessary criteria was patients' consent. In outpatient conditions, at the 1st visit and in 1 year we performed a complex of events: anamnesis collection, clarification of complaints; palpation and auscultation of the heart and main vessels; BP measurement by Korotkov on upper extremities; ECG recording, echocardiography. Biochemical analysis of the whole plasma was done, fasting: we measured glucose level, glycosilated hemoglobin, lipid spectrum (cholesterol, triglycerides, LDL, HDL), clotting system parameters (PI, APTT, fibrinogen), electrolites (K, Mg). Also patients by themselves completed medical questionnaires of a special purpose. We used HADS questionnaire and self-assessment for depressions CED-S. If the increased levels of anxiety and depression were found we prescriben Qudesan® — mitochondrial coenzyme — coenzyme Q10 in dose 60 mg daily for 2 months. The dosage was calculated according to the drug sheet. Results. The data we collected witnesses that clinical efficacy was reached in patients at the background of Qudesan® intake: significantly positively changed psychological status of patients — depression decreased by the scales of specialized questionnaires. Scoring of the influence of that drug was done by comparison of clinical characteristics after treatment. Before treatment the parameters studied were identical that is also confirmed by the absence of significance of their difference (p>0,01). Conclusion. The study led to obtainment of a new data on that inclusion of Q10 containing drug into the standard treatment of AH with 2nd type DM has positive clinical effect that, particularly, leads to a significant decrease of systolic and diastoiic blood pressure, significant decrease of BP variability, significant decrease of blood glucose levels and glycosilated hemoglobin, significant increase of Mg level in blood. Also the positive influence of complex therapy noted on the decrease of anxiety and depression level in patients with AH and DM 2 type.